| Press releases

Formycon Reports Nine-Month Figures for 2018

Formycon increases turnover and raises annual forecast for 2018.


German Equity Forum

November 26 – 28, 2018; Frankfurt/Germany

Financial reports

Annual Report 2017

Published on:
May 7, 2018

  • Forschung_und_Entwicklung_2018_web_en
  • Teaser_mitglied-bio-deutschland-en
  • Teaser_mitglied-biosimilar-medicines-en
  • teaser-powerlist
  • teaser-wachstumschampion-en
  • pipeline-en-teaser
  • slider04
  • slider06

Formycon is a leading independent pure play developer of biosimilars and has become a recognized innovator in this field. The company has extensive experience in the development of complex biological molecules. Formycon’s expertise allows the company to develop high-quality biosimilars that meet the strict regulatory requirements of highly regulated markets such as Europe and the United States. Formycon currently has four biosimilars under development, with further product candidates already identified. Two biosimilar candidates have already been licensed out, one project has been transferred into a joint venture.